Literature DB >> 2751851

The safety and effectiveness of an implanted electromagnetic hearing device.

G A Gates1, J V Hough, W M Gatti, W H Bradley.   

Abstract

The records of 184 patients implanted with the XOMED Audiant Bone Conductor (XOMED Inc, Jacksonville, Fla) prior to March 1988 were reviewed retrospectively to determine the safety of this device. Complications were few and minor in nature. Effectiveness was judged from the audiometric data obtained from the 96 patients in the hearing part of this study, all of whom had improved hearing with the device. The mean preoperative pure-tone air-conduction three-frequency average threshold +/- SD in the implanted ear was 55.8 +/- 10.7-dB hearing level; postoperative average aided warble-tone threshold was 19.9 +/- 8.5-dB hearing level. The average improvement in threshold was 36.0 +/- 13.3 dB. Ninety-three percent of patients achieved socially adequate hearing, ie, mean aided sound-field thresholds of at least 30-dB hearing level, and 81% had thresholds of at least 25-dB hearing level. We conclude that the XOMED Audiant Bone Conductor is a safe and effective device for the surgical correction of conductive hearing loss.

Entities:  

Mesh:

Year:  1989        PMID: 2751851     DOI: 10.1001/archotol.1989.01860320034014

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  4 in total

1.  Bone anchored hearing aids: a second fixture reduces auditory deprivation in Cambridge.

Authors:  V S P Durvasula; H Patel; S Mahendran; R F Gray
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-04-06       Impact factor: 2.503

2.  Current trends in implantable hearing AIDS.

Authors:  M Chasin
Journal:  Trends Amplif       Date:  1997-09

3.  Medical aspects of bone anchored hearing AIDS and middle ear implants.

Authors:  Phillip S Wade
Journal:  Trends Amplif       Date:  2002-06

4.  First clinical experiences with an implantable bone conduction hearing aid at the University of Amsterdam.

Authors:  R J van der Hulst; W A Dreschler; R A Tange
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.